FDA-Drug2022-05-18Class II
MVASI (bevacizumab-awwb), Injection, For Intravenous Infusion After Dilution, 100 mg/4 ml, Single dose vial, Rx only, Manufactured by Amgen Inc. Thousand Oaks, CA 91320-1799, NDC 55513-0206-01
Hazard
Defective container: loose crimp defect, potential loss of container integrity.
Sold states
Nationwide in the USA, Egypt and Lithuania.
Affected count
15,823
Manufactured in
1 Amgen Center Dr, N/A, Thousand Oaks, CA, United States
Products
MVASI (bevacizumab-awwb), Injection, For Intravenous Infusion After Dilution, 100 mg/4 ml, Single dose vial, Rx only, Manufactured by Amgen Inc. Thousand Oaks, CA 91320-1799, NDC 55513-0206-01
Official notice
https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0855-2022More Amgen, Inc. recalls
- FDA-Drug2026-07-01Amgen Corlanor (ivabradine) 7.5mg tablets recalled for foreign substance
- FDA-Drug2026-07-01Amgen Corlanor (ivabradine) 5 mg tablets recalled for foreign substance contamination
- FDA-Drug2026-07-01Amgen Sensipar 60mg tablets recalled for manufacturing quality deviations
- FDA-Drug2026-07-01Amgen Sensipar (cinacalcet) 90mg tablets recalled for manufacturing compliance issues
- FDA-Drug2026-07-01Amgen Sensipar (cinacalcet) 30mg tablets recalled for manufacturing quality deviations
Don't want to check this manually?
We email you a Sunday digest of new federal recalls relevant to parents — free, no credit card. Or upgrade to as-it-happens alerts for the brands you actually own.
Get the Sunday Brief